Neocortical and hippocampal TREM2 protein levels during the progression of Alzheimer's disease

Neurobiology of Aging

Volumn 54, Issue , 2017, Pages 133-143

  Perez, Sylvia E ^a   Nadeem, Muhammad ^a   He, Bin ^a   Miguel, Jennifer C ^a   Malek Ahmadi, Michael H ^b   Chen, Kewei ^b   Mufson, Elliott J ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b BANNER ALZHEIMER S INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Amyloid; Immunohistochemistry; Microglia; Mild cognitive impairment; Tau; TREM2; Western blot

Indexed keywords

AMYLOID PROTEIN; IBA1 PROTEIN; MEMBRANE PROTEIN; MESSENGER RNA; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; TREM2 PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FRONTAL CORTEX; GENE EXPRESSION; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROGLIA; MILD COGNITIVE IMPAIRMENT; NEOCORTEX; NONCOGNITIVE IMPAIRMENT; POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; DISEASE EXACERBATION; GENETICS; METABOLISM; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITIVE DYSFUNCTION; DISEASE PROGRESSION; FEMALE; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; NEOCORTEX; RECEPTORS, IMMUNOLOGIC; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 85016513627     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2017.02.012     Document Type: Article

References (59)

1. Benitez, B.A., Cooper, B., Pastor, P., Jin, S.C., Lorenzo, E., Cervantes, S., Cruchaga, C., TREM2 is associated with the risk of Alzheimer's disease in Spanish population. Neurobiol. Aging, 34, 2013, 1711.
2. Bennett, D.A., Schneider, J.A., Arvanitakis, Z., Kelly, J.F., Aggarwal, N.T., Shah, R.C., Wilson, R.S., Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66 (2006), 1837–1844.
3. Bennett, D.A., Schneider, J.A., Wilson, R.S., Bienias, J.L., Arnold, S.E., Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch. Neurol. 61 (2004), 378–384.
4. Bertram, L., Lill, C.M., Tanzi, R.E., The genetics of Alzheimer disease: back to the future. Neuron 68 (2010), 270–281.
5. Bianchin, M.M., Capella, H.M., Chaves, D.L., Steindel, M., Grisard, E.C., Ganev, G.G., da Silva Júnior, J.P., Neto Evaldo, S., Poffo, M.A., Walz, R., Carlotti Júnior, C.G., Sakamoto, A.C., Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy—PLOSL): a dementia associated with bone cystic lesions. From clinical to genetic and molecular aspects. Cell Mol. Neurobiol. 24 (2004), 1–24.
6. Braak, H., Braak, E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82 (1991), 239–259.
7. Celarain, N., Sánchez-Ruiz de Gordoa, J., Zelaya, M.V., Roldán, M., Larumbe, R., Pulido, L., Echavarri, C., Mendioroz, M., TREM2 upregulation correlates with 5-hydroxymethylcytosine enrichment in Alzheimer's disease hippocampus. Clin. Epigenetics, 8, 2016, 37.
8. Chouery, E., Delague, V., Bergougnoux, A., Koussa, S., Serre, J.L., Mégarbané, A., Mutations in TREM2 lead to pure early-onset dementia without bone cysts. Hum. Mutat. 29 (2008), 194–204.
9. Colonna, M., TREMs in the immune system and beyond. Nat. Rev. Immunol. 3 (2003), 445–453.
10. Frank, S., Burbach, G.J., Bonin, M., Walter, M., Streit, W., Bechmann, I., Deller, T., TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 56 (2008), 1438–1447.
11. Ginsberg, S.D., Mufson, E.J., Counts, S.E., Wuu, J., Alldred, M.J., Nixon, R.A., Che, S., Regional selectivity of rab5 and rab7 protein upregulation in mild cognitive impairment and Alzheimer's disease. J. Alzheimers Dis. 22 (2010), 631–639.
12. Giraldo, M., Lopera, F., Siniard, A.L., Corneveaux, J.J., Schrauwen, I., Carvajal, J., Muñoz, C., Ramirez-Restrepo, M., Gaiteri, C., Myers, A.J., Caselli, R.J., Kosik, K.S., Reiman, E.M., Huentelman, M.J., Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease. Neurobiol. Aging, 34, 2013, 2077.
13. Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J.S., Younkin, S., Hazrati, L., Collinge, J., Pocock, J., Lashley, T., Williams, J., Lambert, J.C., Amouyel, P., Goate, A., Rademakers, R., Morgan, K., Powell, J., St George-Hyslop, P., Singleton, A., Hardy, J., Alzheimer Genetic Analysis Group. TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368 (2013), 117–127.
14. Guerreiro, R.J., Lohmann, E., Brás, J.M., Gibbs, J.R., Rohrer, J.D., Gurunlian, N., Dursun, B., Bilgic, B., Hanagasi, H., Gurvit, H., Emre, M., Singleton, A., Hardy, J., Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 70 (2013), 78–84.
15. Hakola, H.P., Neuropsychiatric and genetic aspects of a new hereditary disease characterized by progressive dementia and lipomembranous polycystic osteodysplasia. Acta Psychiatr. Scand. Suppl. 232 (1972), 1–173.
16. Henjum, K., Almdahl, I.S., Årskog, V., Minthon, L., Hansson, O., Fladby, T., Nilsson, L.N., Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. Alzheimers Res. Ther., 8, 2016, 17.
17. Heslegrave, A., Heywood, W., Paterson, R., Magdalinou, N., Svensson, J., Johansson, P., Öhrfelt, A., Blennow, K., Hardy, J., Schott, J., Mills, K., Zetterberg, H., Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Mol. Neurodegener., 11, 2016, 3.
18. Jiang, T., Tan, L., Zhu, X.C., Zhang, Q.Q., Cao, L., Tan, M.S., Wang, H.F., Chen, Q., Zhang, Y.D., Yu, J.T., Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer's disease. Neuropsychopharmacology 39 (2014), 2949–2962.
19. Jones, B.M., Bhattacharjee, S., Dua, P., Hill, J.M., Zhao, Y., Lukiw, W.J., Regulating amyloidogenesis through the natural triggering receptor expressed in myeloid/microglial cells 2 (TREM2). Front Cell Neurosci., 8, 2014, 94.
20. Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P.V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A.I., Lah, J.J., Rujescu, D., Hampel, H., Giegling, I., Andreassen, O.A., Engedal, K., Ulstein, I., Djurovic, S., Ibrahim-Verbaas, C., Hofman, A., Ikram, M.A., van Duijn, C.M., Thorsteinsdottir, U., Kong, A., Stefansson, K., Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. 368 (2013), 107–116.
21. Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., Tahirovic, S., Lleó, A., Alcolea, D., Fortea, J., Willem, M., Lammich, S., Molinuevo, J.L., Sánchez-Valle, R., Antonell, A., Ramirez, A., Heneka, M.T., Sleegers, K., van der Zee, J., Martin, J.J., Engelborghs, S., Demirtas-Tatlidede, A., Zetterberg, H., Van Broeckhoven, C., Gurvit, H., Wyss-Coray, T., Hardy, J., Colonna, M., Haass, C., TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci. Transl. Med., 6, 2014, 243ra86.
22. Klesney-Tait, J., Turnbull, I.R., Colonna, M., The TREM receptor family and signal integration. Nat. Immunol. 7 (2006), 1266–1273.
23. Le Ber, I., De Septenville, A., Guerreiro, R., Bras, J., Camuzat, A., Caroppo, P., Lattante, S., Couarch, P., Kabashi, E., Bouya-Ahmed, K., Dubois, B., Brice, A., Homozygous TREM2 mutation in a family with atypical frontotemporal dementia. Neurobiol. Aging, 35, 2014, 2419.
24. Lue, L.F., Schmitz, C.T., Serrano, G., Sue, L.I., Beach, T.G., Walker, D.G., TREM2 protein expression changes correlate with Alzheimer's disease neurodegenerative pathologies in post-mortem temporal cortices. Brain Pathol. 25 (2015), 469–480.
25. Ma, L., Allen, M., Sakae, N., Ertekin-Taner, N., Graff-Radford, N.R., Dickson, D.W., Younkin, S.G., Sevlever, D., Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimer's disease brains. Mol. Neurodegener., 11, 2016, 72.
26. Matarin, M., Salih, D.A., Yasvoina, M., Cummings, D.M., Guelfi, S., Liu, W., Nahaboo Solim, M.A., Moens, T.G., Paublete, R.M., Ali, S.S., Perona, M., Desai, R., Smith, K.J., Latcham, J., Fulleylove, M., Richardson, J.C., Hardy, J., Edwards, F.A., A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. Cell Rep. 10 (2015), 633–644.
27. Melchior, B., Garcia, A.E., Hsiung, B.K., Lo, K.M., Doose, J.M., Thrash, J.C., Stalder, A.K., Staufenbie, L.M., Neumann, H., Carson, M.J., Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease. ASN Neuro., 2, 2010, e00037.
28. Mirra, S.S., The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary. Neurobiol. Aging 18 (1997), S91–S94.
29. Mitchell, T.W., Nissanov, J., Han, L.Y., Mufson, E.J., Schneider, J.A., Cochran, E.J., Nissanov, J., Han, L.Y., Bienias, J.L., Lee, V.M., Trojanowski, J.Q., Bennett, D.A., Arnold, S.E., Novel method to quantify neuropil threads in brains from elders with or without cognitive impairment. J. Histochem. Cytochem. 48 (2000), 1627–1638.
30. Montine, T.J., Phelps, C.H., Beach, T.G., Bigio, E.H., Cairns, N.J., Carrillo, M.C., Dickson, D.W., Duyckaerts, C., Frosch, M.P., Masliah, E., Mirra, S.S., Nelson, P.T., Schneider, J.A., Thal, D.R., Thies, B., Trojanowski, J.Q., Vinters, H.V., Montine, T.J., National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 123 (2012), 1–11.
31. Mufson, E.J., Binder, L., Counts, S.E., DeKosky, S.T., de Toledo-Morrell, L., Ginsberg, S.D., Ikonomovic, M.D., Perez, S.E., Scheff, S.W., Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol. 123 (2012), 13–30.
32. Mufson, E.J., He, B., Nadeem, M., Perez, S.E., Counts, S.E., Leurgans, S., Fritz, J., Lah, J., Ginsberg, S.D., Wuu, J., Scheff, S.W., Hippocampal proNGF signaling pathways and β-amyloid levels in mild cognitive impairment and Alzheimer disease. J. Neuropathol. Exp. Neurol. 71 (2012), 1018–1029.
33. Mufson, E.J., Mahady, L., Waters, D., Counts, S.E., Perez, S.E., DeKosky, S.T., Ginsberg, S.D., Ikonomovic, M.D., Scheff, S.W., Binder, L.I., Hippocampal plasticity during the progression of Alzheimer's disease. Neuroscience 309 (2015), 51–67.
34. Mufson, E.J., Malek-Ahmadi, M., Snyder, N., Ausdemore, J., Chen, K., Perez, S.E., Braak stage and trajectory of cognitive decline in noncognitively impaired elders. Neurobiol. Aging 43 (2016), 101–110.
35. Nasu, T., Tsukahara, Y., Terayama, K., A lipid metabolic disease-“membranous lipodystrophy”—an autopsy case demonstrating numerous peculiar membrane-structures composed of compound lipid in bone and bone marrow and various adipose tissues. Acta Pathol. Jpn. 23 (1973), 539–558.
36. Neumann, H., Kotter, M.R., Franklin, R.J.M., Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 132 (2009), 288–295.
37. Newell, K.L., Hyman, B.T., Growdon, J.H., Hedley-Whyte, E.T., Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J. Neuropathol. Exp. Neurol. 58 (1999), 1147–1155.
38. Painter, M.M., Atagi, Y., Liu, C.C., Rademakers, R., Xu, H., Fryer, J.D., Bu, G., TREM2 in CNS homeostasis and neurodegenerative disease. Mol. Neurodegener., 10, 2015, 43.
39. Perez, S.E., Getova, D.P., He, B., Counts, S.E., Geula, C., Desire, L., Coutadeur, S., Peillon, H., Ginsberg, S.D., Mufson, E.J., Rac1b increases with progressive tau pathology within cholinergic nucleus basalis neurons in Alzheimer's disease. Am. J. Pathol. 180 (2012), 526–540.
40. Perez, S.E., He, B., Nadeem, M., Wuu, J., Scheff, S.W., Abrahamson, E.E., Ikonomovic, M.D., Mufson, E.J., Resilience of precuneus neurotrophic signaling pathways despite amyloid pathology in prodromal Alzheimer's disease. Biol. Psychiatry 77 (2015), 693–703.
41. Piaceri, I., Nacmias, B., Sorbi, S., Genetics of familial and sporadic Alzheimer's disease. Front Biosci. 5 (2013), 167–177.
42. Piccio, L., Deming, Y., Del-Águila, J.L., Ghezzi, L., Holtzman, D.M., Fagan, A.M., Fenoglio, C., Galimberti, D., Borroni, B., Cruchaga, C., Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 131 (2016), 925–933.
43. Pottier, C., Wallon, D., Rousseau, S., Rovelet-Lecrux, A., Richard, A.C., Rollin-Sillaire, A., Frebourg, T., TREM2 R47H variant as a risk factor for early-onset Alzheimer's disease. J. Alzheimers Dis. 35 (2013), 45–49.
44. Raha, A.A., Henderson, J.W., Stott, S.R., Vuono, R., Foscarin, S., Friedland, R.P., Zaman, S.H., Raha-Chowdhury, R., Neuroprotective effect of TREM-2 in aging and Alzheimer's disease model. J. Alzheimers Dis. 55 (2016), 199–217.
45. Rezazadeh, M., Khorrami, A., Yeghaneh, T., Talebi, M., Kiani, S.J., Heshmati, Y., Gharesouran, J., Genetic factors affecting late-onset Alzheimer's disease susceptibility. Neuromolecular Med. 18 (2016), 37–49.
46. Rosenthal, S.L., Kamboh, M.I., Late-onset Alzheimer's disease genes and the potentially implicated pathways. Curr. Genet. Med. Rep. 2 (2014), 85–101.
47. Schmid, C.D., Sautkulis, L.N., Danielson, P.E., Cooper, J., Hasel, K.W., Hilbush, B.S., Sutcliffe, J.G., Carson, M.J., Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. J. Neurochem. 83 (2002), 1309–1320.
48. Sessa, G., Podini, P., Mariani, M., Meroni, A., Spreafico, R., Sinigaglia, F., Colonna, M., Panina, P., Meldolesi, J., Distribution and signaling of TREM2/DAP12, the receptor system mutated in human polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy dementia. Eur. J. Neurosci. 20 (2004), 2617–2628.
49. Slattery, C.F., Beck, J.A., Harper, L., Adamson, G., Abdi, Z., Uphill, J., Campbell, T., Druyeh, R., Mahoney, C.J., Rohrer, J.D., Kenny, J., Lowe, J., Leung, K.K., Barnes, J., Clegg, S.L., Blair, M., Nicholas, J.M., Guerreiro, R.J., Rowe, J.B., Ponto, C., Zerr, I., Kretzschmar, H., Gambetti, P., Crutch, S.J., Warren, J.D., Rossor, M.N., Fox, N.C., Collinge, J., Schott, J.M., Mead, S., R47H TREM2 variant increases risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia. Alzheimers Dement. 10 (2014), 602–608.
50. Strobel, S., Grünblatt, E., Riederer, P., Heinsen, H., Arzberger, T., Al-Sarraj, S., Troakes, C., Ferrer, I., Monoranu, C.M., Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer's disease progression: CX3CL1, TREM2, and PPARγ. J. Neural. Transm. 122 (2015), 1069–1076.
51. Suárez-Calvet, M., Kleinberger, G., Araque Caballero, M.Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J.D., Sánchez-Valle, R., Antonell, A., Rami, L., Molinuevo, J.L., Brosseron, F., Traschütz, A., Heneka, M.T., Struyfs, H., Engelborghs, S., Sleegers, K., Van Broeckhoven, C., Zetterberg, H., Nellgård, B., Blennow, K., Crispin, A., Ewers, M., Haass, C., sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. Sci. Transl. Med., 8, 2016, 369ra178.
52. Takahashi, K., Rochford, C.D., Neumann, H., Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J. Exp. Med. 201 (2005), 647–657.
53. Ulrich, J.D., Finn, M.B., Wang, Y., Shen, A., Mahan, T.E., Jiang, H., Stewart, F.R., Piccio, L., Colonna, M., Holtzman, D.M., Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2. Mol. Neurodegener., 9, 2014, 20.
54. Verloes, A., Maquet, P., Sadzot, B., Vivario, M., Thiry, A., Franck, G., Nasu-Hakola syndrome: polycystic lipomembranous osteodysplasia with sclerosing leucoencephalopathy and presenile dementia. J. Med. Genet. 34 (1997), 753–757.
55. Wang, Y., Cella, M., Mallinson, K., Ulrich, J.D., Young, K.L., Robinette, M.L., Gilfillan, S., Krishnan, G.M., Sudhakar, S., Zinselmeyer, B.H., Holtzman, D.M., Cirrito, J.R., Colonna, M., TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160 (2015), 1061–1071.
56. Wang, Y., Ulland, T.K., Ulrich, J.D., Song, W., Tzaferis, J.A., Hole, J.T., Yuan, P., Mahan, T.E., Shi, Y., Gilfillan, S., Cella, M., Grutzendler, J., DeMattos, R.B., Cirrito, J.R., Holtzman, D.M., Colonna, M., TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J. Exp. Med. 213 (2016), 667–675.
57. Yeh, F.L., Wang, Y., Tom, I., Gonzalez, L.C., Sheng, M., TREM2 Binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. Neuron 91 (2016), 328–340.
58. Yuan, P., Condello, C., Keene, C.D., Wang, Y., Bird, T.D., Paul, S.M., Luo, W., Colonna, M., Baddeley, D., Grutzendler, J., TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron 90 (2016), 724–739.
59. Zhao, Y., Bhattacharjee, S., Jones, B.M., Dua, P., Alexandrov, P.N., Hill, J.M., Lukiw, W.J., Regulation of TREM2 expression by an NF-кB-sensitive miRNA-34a. Neuroreport 24 (2013), 318–323.